Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit

Presentation Date/Time: Monday, June 24, 2024; 11:45 a.m. EDT Presentation Format: Panel Discussion – "Novel Immunological Mechanisms for Dermatologic Disorders" Forward-Looking Statements Joyce Allaire (investors) LifeSci Advisors Oppenheimer Novel Targets in Immunology Summit Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk ...